A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men or Women with a clinical diagnosis of Probable AD
MMSE score 12 to 22 inclusive
Age >50 and <90 years
Received at least 4 months of a stable dose of donepezil 10mg QD for AD
Brain CT or MRI scan Consistent with a primary diagnosis of AD within 24 months
Neurological examination without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)
No history or evidence of any other CNS disorder that could be interpreted as a cause of dementia
No diagnosis of vascular dementia
No history of significant psychiatric illness such as schizophrenia or bipolar affective disorder. Subjects with major depressive disorder on a stable dose of an antidepressant for >6 months may be eligible
No evidence of the following: current vitamin B12 deficiency, positive syphilis serology, positive HIV test, or abnormalities in thyroid function
No cognitive rehabilitation within 6 months of the study
Subject has a regular caregiver willing to attend all study visits
Signed informed consent by the subject (and legal guardian, if applicable)
No history of drug or alcohol abuse
No clinically significant laboratory abnormalities or medical history
No investigational drug within 30 days of Randomization
Cannot receive memantine within 2 months of enrollment
No other prescription acetylcholinesterase inhibitors for AD (other than donepezil) within 4 months of enrollment
No clinically significant ECG abnormalities or cardiac history
No history of uncontrolled seizure disorder within 12 months of enrollment
Cannot be taking MAO inhibitors, bupropion,fluoxetine, paroxetine, quinidine
No history of malignancy within 3 years of randomization